* This switch is intended for paliperidone long acting (Xeplion®, 30 days)
There are 3 different formulations of paliperidone extended release Xeplion® = Paliperidone long acting / 30 days Trivecta® = Paliperidone super long acting / 90 days Byannli® = Paliperidone ultra long acting / 178 days | ||||
| ||||
Switch medication from Paliperidone ER to Partial agonist.[1]
[2]
Partial agonist is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'partial agonist' group from anotherdrug should be read as partial agonist-anotherdrug. Similarly, a switch from a member of the 'partial agonist' group to anotherdrug should be read as anotherdrug-partial agonist.
Stop Paliperidone ER - Day 1: Last depot injection
Start Partial agonist- Start drug at target dose on the day you would normally have injected the next depot.
More information- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[3]
— Paliperidone ER — Partial agonist
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.